A new medication is being studied for its potential to repair damaged myelin sheaths and restore function to patients with secondary-progressive multiple sclerosis.
For the treatment of secondary-progressive multiple sclerosis (SPMS), NDC-1308−a small molecule that activates intracellular pathways for oligodendrocyte progenitor cell (OPC) differentiation−showed favorable pharmacokinetic properties and was safe in a mice study.
“NDC-1308 possesses many desirable qualities for a therapeutic to treat [multiple sclerosis (MS)],” said study researcher Steven H. Nye, PhD, who is vice-president of discovery at ENDECE (Mequon, Wisconsin). “In particular, it … readily traverses the blood-brain barrier where it can induce OPCs in the [central nervous system (CNS)] to differentiate into cells that synthesize and maintain the myelin sheath, in a similar manner thought to occur in healthy individuals.”
Read Full Article: Study Shows Potential of Novel Compound to Treat Multiple Sclerosis